MDA-19 – synthetic, strong CB2 agonist


Design and synthesis of a novel series of N-alkyl isatin acylhydrazone derivatives that act as selective cannabinoid receptor 2 agonists for the treatment of neuropathic pain.

(abst – 2008)            


Pharmacological characterization of a novel cannabinoid ligand, MDA19, for treatment of neuropathic pain.      (full – 2010)                             


Studies demonstrate analgesic properties of synthetic cannabinoid (news – 2010)  cannabinoid.aspx

Share a link for